The following trials provide information to treat various types of disease of the brain and the central and local nervous systems, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A single-centre, randomised, double-blind, placebo controlled Phase I study in two parts: Part A to assess a safe and tolerable supratherapeutic dose of TC-5214 after single ascending oral doses in healthy male subjects, followed by Part B: A four-period double-dummy crossover study to investigate the effect of 2 single doses (therapeutic and supratherapeutic) of TC-5214 on the QT/QTc interval, compared to placebo, using moxifloxacin (Avelox®) as a positive control, in healthy male subjects.
- collapse A non – interventional study to Investigating the ratio of Mis-diagnosed bipolar symptoms in Patient diagnosed as with treatment Resistant major depressive disorder (MDD).
- collapse A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder with an Inadequate Response to Antidepressant Therapy
- collapse RECONNECT-S ALPHA: A Non-interventional Study to Observe Real-life Allocation of Antipsychotics in the Acute Inpatient Management of Schizophrenia
- collapse Prospective, observational study for the maintenance treatment of patients with Bipolar Disorder I and II in Greece.
- collapse An Investigation of the Antidepressant Efficacy of a Selective, High, Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder
- collapse IBIS: Italian Burden of Illness on Schizophrenia & bipolar disorder
- collapse Seroquel XR in the long term treatment of schizophrenia focus on affective symptoms
- collapse A Phase I, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics after Single Ascending Oral Doses of AZD2066 in Japanese Healthy Male Subjects.
- collapse A Phase I, Single-centre, Randomised, Double-blind, Placebo-controlled Parallel group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Volunteers after Oral Single Ascending Doses.
